Minerva Neurosciences Inc (NERV)
2.33
-0.03
(-1.27%)
USD |
NASDAQ |
May 01, 16:00
2.33
0.00 (0.00%)
After-Hours: 20:00
Minerva Neurosciences Cash from Financing (Quarterly): 0.00 for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | -0.0867M |
| June 30, 2023 | 19.69M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | -0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 60.00M |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 7.136M |
| June 30, 2020 | 5.305M |
| March 31, 2020 | 0.7976M |
| December 31, 2019 | -0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.525M |
| December 31, 2018 | 0.1651M |
| September 30, 2018 | -0.9072M |
| Date | Value |
|---|---|
| June 30, 2018 | -1.313M |
| March 31, 2018 | -1.290M |
| December 31, 2017 | -1.267M |
| September 30, 2017 | 40.97M |
| June 30, 2017 | -0.9704M |
| March 31, 2017 | 8.436M |
| December 31, 2016 | 0.0551M |
| September 30, 2016 | -0.536M |
| June 30, 2016 | 58.50M |
| March 31, 2016 | 18.54M |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | -0.2322M |
| March 31, 2015 | 38.57M |
| December 31, 2014 | -0.0303M |
| September 30, 2014 | 50.35M |
| June 30, 2014 | 0.8828M |
| March 31, 2014 | 0.3946M |
| December 31, 2013 | 1.932M |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 1.85M |
| March 31, 2013 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.0867M
Minimum
Sep 2023
60.00M
Maximum
Mar 2021
4.886M
Average
--
Median
Jun 2019
Cash from Financing (Quarterly) Benchmarks
| Viking Therapeutics Inc | 606.04M |
| Janux Therapeutics Inc | 0.831M |
| ACADIA Pharmaceuticals Inc | 5.434M |
| Karyopharm Therapeutics Inc | 0.264M |
| Calidi Biotherapeutics Inc | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -5.991M |
| Free Cash Flow | -14.78M |
| Free Cash Flow Per Share (Quarterly) | -0.7904 |
| Free Cash Flow Yield | -97.62% |